Vaccination campaign to contrast the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has raised the issue of vaccine immunogenicity in special populations such as people with multiple sclerosis (PwMS) on highly effective disease modifying treatments (DMTs). While humoral responses to SARS-CoV-2 mRNA vaccines have been well characterized in the general population and in PwMS, very little is known about cell-mediated responses in conferring protection from SARS-CoV-2 infection and severe coronavirus disease-2019 (COVID-19).

Iannetta, M., Landi, D., Cola, G., Campogiani, L., Malagnino, V., Teti, E., et al. (2021). B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. FRONTIERS IN IMMUNOLOGY, 12, 796482 [10.3389/fimmu.2021.796482].

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications

Iannetta, Marco;Landi, Doriana;Malagnino, Vincenzo;Teti, Elisabetta;Buccisano, Francesco;Grelli, Sandro;Andreoni, Massimo;Marfia, Girolama Alessandra;Sarmati, Loredana
2021

Abstract

Vaccination campaign to contrast the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has raised the issue of vaccine immunogenicity in special populations such as people with multiple sclerosis (PwMS) on highly effective disease modifying treatments (DMTs). While humoral responses to SARS-CoV-2 mRNA vaccines have been well characterized in the general population and in PwMS, very little is known about cell-mediated responses in conferring protection from SARS-CoV-2 infection and severe coronavirus disease-2019 (COVID-19).
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26
English
Con Impact Factor ISI
CD20
COVID
IGRA
T-lymphocyte
fingolimod
natalizumab
ocrelizumab
peptides
Adult
B-Lymphocytes
BNT162 Vaccine
Female
Humans
Male
Middle Aged
Multiple Sclerosis
SARS-CoV-2
T-Lymphocytes
COVID-19
Vaccination
Iannetta, M., Landi, D., Cola, G., Campogiani, L., Malagnino, V., Teti, E., et al. (2021). B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. FRONTIERS IN IMMUNOLOGY, 12, 796482 [10.3389/fimmu.2021.796482].
Iannetta, M; Landi, D; Cola, G; Campogiani, L; Malagnino, V; Teti, E; Coppola, L; Di Lorenzo, A; Fraboni, D; Buccisano, F; Grelli, S; Mozzani, M; Zingaropoli, Ma; Ciardi, Mr; Nisini, R; Bernardini, S; Andreoni, M; Marfia, Ga; Sarmati, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies Immunological Patterns and Clinical Implications.pdf

solo utenti autorizzati

Licenza: Non specificato
Dimensione 5.52 MB
Formato Adobe PDF
5.52 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/306416
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 9
  • ???jsp.display-item.citation.isi??? ND
social impact